By Stephen Nakrosis

Arrowhead Pharmaceuticals Inc. on Monday said it entered an exclusive license agreement with GlaxoSmithKline which will see GSK develop and commercialize Arrowhead's ARO-HSD.

Arrowhead said ARO-HSD is an "investigational RNA interference therapeutic in a Phase 1/2 trial that is currently being developed as a treatment for patients with nonalcoholic steatohepatitis."

Arrowhead will receive an upfront payment of $120 million. Arrowhead is also eligible for additional payments tied to future trials and regulatory approval, as well as for commercial milestone payments and royalties, according to the companies.

GlaxoSmithKline will receive an exclusive license to develop and commercialize ARO-HSD in all territories except Greater China, which will be retained by Arrowhead, the companies said.

The deal is expected to close in the first quarter of next year.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

November 22, 2021 16:40 ET (21:40 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Gsk Charts.